Botulinum Toxin Type A
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Botulinum Toxin Type A: From Neuromuscular Indications to Parkinson Disease
One-Sentence Summary
Botulinum toxin type A is a neurotoxin that blocks acetylcholine release at nerve endings, and it is registered in Singapore as Botox (an injectable powder). The TxGNN model predicts it may be useful for Parkinson disease (symptom management), the strongest-supported of its top predictions, with 6 clinical trials and 20 publications currently supporting this direction. Evidence points to relief of specific symptoms, not disease modification.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the data compiled for this report (the approved indication text on the Singapore licence is blank) |
| Predicted New Indication | Parkinson disease (symptom management). This is the best-evidenced of the top 10 predictions; the highest-scoring prediction, primary hereditary glaucoma, has no supporting evidence. |
| TxGNN Prediction Score | 77.69% for Parkinson disease (rank 7 of the predictions). The top-ranked prediction, primary hereditary glaucoma, scored 89.37%. |
| Evidence Level | L1 (Parkinson disease) |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Proceed with Guardrails |
Note on prediction ranking: The top-ranked predictions by TxGNN score were primary hereditary glaucoma (89.4%), parkinsonian disorder (88.8%) and open-angle glaucoma (88.8%). Both glaucoma entries and several others (insomnia, bronchitis, juvenile and autosomal recessive parkinsonism) have no supporting trials or only off-target literature, and are rated Hold. This report focuses on the Parkinson-related predictions because they carry the only substantial evidence. "Parkinsonian disorder" (rank 2, score 88.8%) and "Parkinson disease" (rank 7, score 77.7%) draw on the same trials.
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. From general pharmacology, botulinum toxin A blocks release of acetylcholine from presynaptic terminals (via the SNARE protein complex) at neuromuscular junctions and autonomic cholinergic synapses. This produces a local, temporary reduction in muscle activity and glandular secretion.
That mechanism plausibly addresses several focal, symptom-level problems in Parkinson disease:
- Sialorrhea (drooling), through cholinergic innervation of the salivary glands
- Limb tremor and dystonia-associated pain, through reduced overactive muscle activity
- Overactive bladder and possibly constipation, through autonomic effects
It does not act on dopaminergic neurodegeneration, so any benefit is symptomatic rather than disease-modifying. For the glaucoma, insomnia and bronchitis predictions, the data contain no supported mechanistic link.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02091739 | Phase 3 | Completed | 184 | Randomised, double-blind, placebo-controlled trial of two doses of NT 201 (75 U or 100 U) for chronic troublesome sialorrhea in various neurological conditions; the strongest direct evidence. Results should be checked, as the registry title is truncated. |
| NCT04277247 | Phase 2/3 | Unknown | 40 | Onabotulinumtoxin A vs placebo for foot dystonia-associated pain in Parkinson disease |
| NCT02668497 | Phase 2 | Unknown | 50 | Kinematics-guided injection for upper limb Parkinson tremor |
| NCT06094309 | Not applicable | Unknown | 20 | Randomised pilot study of freezing of gait |
| NCT00477802 | Phase 4 | Terminated | 8 | Cervical injections for levodopa-induced dyskinesias; terminated early, so uninformative |
| NCT03069911 | Phase 1 | Terminated | 3 | Depression in Parkinson disease; terminated at n=3, uninformative |
For the other predictions, only one trial was listed (NCT00246155, bronchitis), and it studies back muscle function in low back pain, so it is unrelated.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 16440332 | 2006 | RCT | Movement Disorders | Double-blind, placebo-controlled study in 32 patients; 50 U Botox per parotid gland reduced drooling frequency and related disability |
| 29334040 | 2018 | RCT (crossover) | Can J Neurol Sci | Randomised, double-blind, placebo-controlled crossover study of limb pain in advanced Parkinson disease |
| 28837826 | 2018 | Review | Toxicon | Review of botulinum toxin in parkinsonism; high level of evidence for sialorrhea |
| 21791351 | 2011 | Clinical study | J Urol | 100 U intradetrusor injection in Parkinson disease patients with refractory overactive bladder, 6-month follow-up |
| 26566459 | 2015 | Open-label study | Tremor Other Hyperkinet Mov | 38-week study using sensor-guided incobotulinumtoxinA for Parkinson tremor |
| 34497068 | 2021 | Clinical study | Neurology | Relationship between botulinum toxin, tremor amplitude and cortical excitability in tremor-dominant Parkinson disease |
| 41745739 | 2026 | Clinical study | Toxins | Drooling injections into salivary glands also improved swallowing in 20 Parkinson patients |
| 34828584 | 2021 | Systematic review and meta-analysis | Healthcare (Basel) | Botulinum toxin A in restless legs syndrome (rank 6 prediction, L3) |
| 17561538 | 2006 | Case report | J Clin Sleep Med | Successful treatment of refractory restless legs syndrome |
| 39559314 | 2024 | Observational study | Int J Ophthalmol | Link between blepharospasm and anxiety, depression and sleep disorder; indirect and not evidence for treating insomnia |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN14203P | Botox® Powder for Solution for Injection 200 Units/Vial (Allergan Pharmaceuticals Ireland) | Injection, powder, for solution | Not stated in the available data |
Safety Considerations
Drug interactions: 41 interactions were identified; the 20 shown in the data compiled for this report include:
- Major: aminoglycosides and related antibiotics (kanamycin, neomycin, streptomycin) and polymyxin B, which may add to neuromuscular blockade
- Moderate: anticholinergic agents (atropine, glycopyrronium, hyoscyamine, scopolamine, dicyclomine, trospium and others) and sedating antihistamines (promethazine, brompheniramine, carbinoxamine and others)
For use in Parkinson disease, the symptom-management rationale also calls for monitoring for dysphagia and spread of toxin effect beyond the injection site. Package insert warnings and contraindications were not available, so please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails (for Parkinson disease symptom management only)
Rationale:
- One completed Phase 3 randomised placebo-controlled trial (sialorrhea, n=184), supported by several randomised and open-label studies and reviews, supports symptom-level use in Parkinson disease. The other trials are small, terminated or of unknown status, and the evidence does not support disease modification.
- The glaucoma, insomnia, bronchitis, juvenile parkinsonism and autosomal recessive Parkinson disease predictions lack supporting evidence and should remain on Hold. Restless legs syndrome is a research question only.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA (a blocking gap for safety screening)
- The Singapore approved indication text and a confirmed original indication
- Mechanism of action data from DrugBank
- Confirmation of the NCT02091739 results and its sialorrhea endpoint
- A guardrail plan covering injection site and dose limits, monitoring for dysphagia and toxin spread, and review of interacting medicines (aminoglycosides, polymyxin B, anticholinergics)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.